Key Highlights
- BillionToOne shares closed down 39% at $91.65.
- Q2 revenue reached $109.45 million, up 64% year-over-year.
- Oncology testing revenue surged 176% to $13.7 million.
- The company reaffirmed full-year 2026 revenue guidance of $450 million to $465 million.
BillionToOne, Inc. (NASDAQ: BLLN) shares closed down 39% at $91.65 despite the company disclosing second-quarter revenue of $109.45 million, representing a robust 64% year-over-year increase fueled by a 35% rise in test volume and a 21% improvement in average selling price to $551.
What Happened
The company achieved net income of $0.15 per share, meeting analyst consensus, while oncology testing revenue surged 176% to $13.7 million, with gross margins reaching 70% and positive operating income of $5.5 million.
Market Reaction
Shares fell sharply despite the strong growth metrics and reaffirmed guidance, a decline that stands in contrast to the generally constructive underlying results, including test volume growth, pricing improvement, and profitability.
Outlook
Management reaffirmed its full-year 2026 revenue outlook of $450 million to $465 million; the disclosed information does not specify a reason for today's decline despite this reaffirmed guidance and the quarter's strong results.
Why did BillionToOne shares fall 39% despite strong Q2 results?
The disclosed information does not specify a reason for the decline beyond the reported results and reaffirmed guidance.
How much did BillionToOne's oncology testing revenue grow?
176% to $13.7 million.
What is BillionToOne's full-year 2026 revenue guidance?
$450 million to $465 million, reaffirmed with the Q2 report.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...